Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a report issued on Wednesday,Benzinga reports. They currently have a $22.00 target price on the stock. Needham & Company LLC’s price objective suggests a potential upside of 136.31% from the stock’s previous close.

A number of other brokerages have also recently weighed in on STOK. Leerink Partners assumed coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Chardan Capital began coverage on Stoke Therapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $24.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $21.29.

Stoke Therapeutics Stock Down 15.5 %

STOK opened at $9.31 on Wednesday. Stoke Therapeutics has a 52 week low of $4.09 and a 52 week high of $17.58. The business has a fifty day simple moving average of $12.12 and a 200-day simple moving average of $13.14. The firm has a market cap of $493.12 million, a P/E ratio of -4.43 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The company had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Sell-side analysts expect that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 13,945 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $178,217.10. Following the sale, the insider now owns 47,332 shares of the company’s stock, valued at approximately $604,902.96. This trade represents a 22.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Jonathan Allan sold 9,696 shares of the company’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $123,914.88. Following the completion of the transaction, the general counsel now owns 35,142 shares of the company’s stock, valued at approximately $449,114.76. The trade was a 21.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,849 shares of company stock worth $809,421 over the last ninety days. Corporate insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of STOK. Quest Partners LLC purchased a new position in shares of Stoke Therapeutics during the second quarter worth about $29,000. Intech Investment Management LLC acquired a new position in Stoke Therapeutics during the third quarter worth approximately $160,000. The Manufacturers Life Insurance Company lifted its stake in Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after buying an additional 1,994 shares during the last quarter. Mesirow Financial Investment Management Inc. acquired a new stake in shares of Stoke Therapeutics in the third quarter valued at approximately $192,000. Finally, Profund Advisors LLC purchased a new position in shares of Stoke Therapeutics during the second quarter worth approximately $201,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.